GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (NAS:ARWR) » Definitions » Shiller PE Ratio

Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) Shiller PE Ratio : (As of May. 31, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arrowhead Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Arrowhead Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals Shiller PE Ratio Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arrowhead Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arrowhead Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Shiller PE Ratio falls into.



Arrowhead Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Arrowhead Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Arrowhead Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.02/131.7762*131.7762
=-1.020

Current CPI (Mar. 2024) = 131.7762.

Arrowhead Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.220 100.560 -0.288
201409 -0.440 100.428 -0.577
201412 -0.410 99.070 -0.545
201503 -0.510 99.621 -0.675
201506 -0.270 100.684 -0.353
201509 -0.410 100.392 -0.538
201512 -0.320 99.792 -0.423
201603 -0.350 100.470 -0.459
201606 -0.320 101.688 -0.415
201609 -0.340 101.861 -0.440
201612 -0.170 101.863 -0.220
201703 -0.080 102.862 -0.102
201706 -0.070 103.349 -0.089
201709 -0.150 104.136 -0.190
201712 -0.180 104.011 -0.228
201803 -0.180 105.290 -0.225
201806 -0.180 106.317 -0.223
201809 -0.120 106.507 -0.148
201812 0.130 105.998 0.162
201903 0.240 107.251 0.295
201906 0.210 108.070 0.256
201909 0.110 108.329 0.134
201912 -0.030 108.420 -0.036
202003 -0.200 108.902 -0.242
202006 -0.130 108.767 -0.158
202009 -0.480 109.815 -0.576
202012 -0.200 109.897 -0.240
202103 -0.260 111.754 -0.307
202106 -0.290 114.631 -0.333
202109 -0.610 115.734 -0.695
202112 -0.600 117.630 -0.672
202203 0.410 121.301 0.445
202206 -0.680 125.017 -0.717
202209 -0.810 125.227 -0.852
202212 -0.390 125.222 -0.410
202303 0.450 127.348 0.466
202306 -0.960 128.729 -0.983
202309 -1.020 129.860 -1.035
202312 -1.240 129.419 -1.263
202403 -1.020 131.776 -1.020

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arrowhead Pharmaceuticals  (NAS:ARWR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Arrowhead Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Executives
James C Hamilton other: Senior Vice President 177 EAST COLORADO BLVD, SUITE 700, PASADENA CA 91105
Victoria Vakiener director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Mauro Ferrari director 201 SOUTH LAKE AVENUE, PASADENA CA 91101
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Douglas B Given director C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Tracie Oliver officer: Chief Commercial Officer 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Patrick O'brien officer: General Counsel 225 S. LAKE AVENUE SUITE 1050, PASADENA CA 91101
Martin Javier San officer: Chief Medical Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Kenneth Allen Myszkowski officer: CFO ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Christopher Richard Anzalone director, officer: President and CEO ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Adeoye Y Olukotun director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Backer Marianne De director 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Michael S Perry director C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
James Hassard officer: Chief Commercial Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Curt Bradshaw officer: Chief Scientific Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105